Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.57 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485867 | 0.91 | EGFR (0.67) | EGFRERBB2GAKERBB4 | |
| SCHEMBL6484264 | 0.90 | EGFR (0.62) | EGFRERBB2ERBB4 | |
| SCHEMBL6496763 | 0.88 | EGFR (0.73) | EGFRERBB2GAK | |
| SCHEMBL6484214 | 0.88 | EGFR (0.66) | EGFRERBB2GAKERBB4 | |
| SCHEMBL6487016 | 0.88 | EGFR (0.77) | EGFRERBB2GAK | |
| SCHEMBL6484261 | 0.86 | EGFR (0.63) | EGFRERBB2ERBB4 | |
| SCHEMBL6486121 | 0.86 | EGFR (0.70) | EGFRERBB2 | |
| SCHEMBL6496915 | 0.85 | EGFR (0.69) | EGFRERBB2GAK | |
| SCHEMBL6483126 | 0.84 | EGFR (0.79) | EGFRERBB2GAK | |
| SCHEMBL6484437 | 0.83 | EGFR (0.66) | EGFRERBB2GAKERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | claimed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | claimed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | claimed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | EGFR 20/4885ERBB2 1/4885GAK 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.